Back to top
more

Syndax Pharmaceuticals (SNDX)

(Real Time Quote from BATS)

$23.57 USD

23.57
67,268

+0.29 (1.25%)

Updated Jul 24, 2024 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura

by Zacks Equity Research

Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.

Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why

by Zacks Equity Research

Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) closed at $28.98 in the latest trading session, marking a +0.98% move from the prior day.

GSK Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.

Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $26.47, marking a -0.45% move from the previous day.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Boeing, Starbucks, Syndax Pharma in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Editas (EDIT) Moves Ahead With its Portfolio Reprioritization

by Zacks Equity Research

Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.

Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication

by Zacks Equity Research

The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.

Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal

by Zacks Equity Research

Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.

Angion (ANGN) Down on Merger Agreement With Private Biotech

by Zacks Equity Research

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Are You Looking for a Top Momentum Pick? Why Syndax Pharmaceuticals (SNDX) is a Great Choice

by Zacks Equity Research

Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Syndax Pharmaceuticals (SNDX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $26.46, marking a +0.57% move from the previous day.

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

by Zacks Equity Research

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.

First Wave (FWBI) IND Filing Under FDA's Review, Stock Up

by Zacks Equity Research

First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.

Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan

by Zacks Equity Research

Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.

Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?

by Zacks Equity Research

Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base

by Zacks Equity Research

The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.

ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection

by Zacks Equity Research

Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $25.62, marking a -1.16% move from the previous day.

Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe

by Zacks Equity Research

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.

bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook

by Zacks Equity Research

bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

by Zacks Equity Research

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.